Astrazeneca Share Discussion Threads

[adrian j boris] 25/4/2022 10:24

AstraZeneca PLC said Monday that its liver cancer treatment tremelimumab was accepted for priority review by U.S. federal health regulators.

The Anglo-Swedish pharmaceutical giant said the action date for the U.S. Food and Drug Administration's regulatory decision is expected in the fourth quarter of 2022.

The company said a Phase 3 study includes a dose of tremelimumab added to the immunotherapy Imfinzi, aiming to improve overall survival of patients with unresectable liver cancer.

"The Himalaya Phase III trial showed an unprecedented three-year overall survival in this setting with a single priming dose of tremelimumab added to Imfinzi, highlighting the potential for this regimen to improve longer-term survival outcomes," Susan Galbraith, AstraZeneca's executive vice president, oncology research and development, said.



Write to Michael Susin at [e-mail]



(END) Dow Jones Newswires

April 25, 2022 02:48 ET (06:48 GMT)

[hotfinance14] 25/4/2022 07:49

Big news on the liver cancer trial this morning.

[maywillow] 19/4/2022 08:13

AstraZeneca PLC and Daiichi Sankyo Co. said Tuesday that Enhertu, a cancer treatment, has been accepted by the U.S. Food and Drug Administration for priority review for patients with previously treated HER2-mutant metastatic non-small cell lung cancer.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease and the designation shortens the review period.

The pharmaceutical companies said the FDA based its decision on a pivotal Destiny-Lung01 trial which showed that Enhertu was the first HER2-directed therapy to show a strong and robust tumor response. It added that the FDA action date for their regulatory decision is during the third quarter of 2022.

The HER2 protein is expressed on the surface of many types of tumors and is one of many biomarkers expressed in breast cancer tumors.

"Enhertu is being further assessed in a comprehensive clinical development program evaluating efficacy and safety across multiple HER2-targetable cancers, including breast, gastric, lung and colorectal cancers," AstraZeneca said.



Write to Anthony O. Goriainoff at [e-mail]



(END) Dow Jones Newswires

April 19, 2022 02:40 ET (06:40 GMT)

[gateside] 12/4/2022 18:09

Filled the gaps nicely on the chart

[montyhedge] 12/4/2022 17:58

Had a superb run, just a bit of profit taking.

[waldron] 12/4/2022 12:44

ASTRAZENECA : Buy rating from Berenberg
04/12/2022 | 12:40pm BST

In a research note published by Luisa Hector, Berenberg advises its customers to buy the stock. The target price is revised upwards from GBX 10000 to GBX 12000.

[arja] 08/4/2022 19:40

have not followed this stock for a while - what a mistake . now chart shows a NOR situation and how long is s piece of string !

[chc15] 08/4/2022 16:27

Long term, holder, yes institutions must be piling in with new cash.

[our haven] 08/4/2022 16:03

Institutions I assume. I bought a fair amount, in my terms before the rise and am happily holding.

[mapocho] 08/4/2022 15:45

I'm buying it...

[paa65] 08/4/2022 14:43

Amazed there is so little chatter on this board. Up 25% in a month. Keeping entire FTSE up whilst Europe and US markets fall.But no interest here? Who is buying this?

[la forge] 07/4/2022 07:37

James Gordon from JP Morgan retains his positive opinion on the stock with a Buy rating.


The target price is reviewed upwards from GBX 10000 to GBX 12000.

[misca2] 06/4/2022 17:00

Analysts at Deutsche Bank hiked their target price for AstraZeneca shares from 10,500.0p to 11,500.0p, telling clients it saw no reason to tilt towards so-called 'value' names in the space and away from 'growth'.

Deutsche Bank conceded that an environment of rising interest rates would normally hardly be seen as auguring positively for a defensive sector to outperform.

However, DB highlighted that these weren't exactly normal times.

"This being a geopolitically-challenged stagflationary-susceptible situation, normal perhaps doesn't apply and indeed pharma has had a strong relative start to the year that may well continue," explained DB.

Within the sector, more highly-valued growth names such as AstraZeneca and Novo Nordisk had been the standout outperformers, versus the likes of GlaxoSmithKline, Novartis or Sanofi.

[philanderer] 06/4/2022 10:09

Deutsche Bank raises AstraZeneca price target to 11,500 (10,500) pence - 'buy'

[chc15] 05/4/2022 16:24

As mentioned, big momentum here, institutions buying at this level, so why sell.

[dudishes] 05/4/2022 15:59

WD Waldron, good forecast!

[waldron] 05/4/2022 07:15

Todays the day it might well break thru an important Resistence level

[waldron] 05/4/2022 07:14

(MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) said Monday its AZD8233 drug at 50-milligram dose lowered the levels of low-density lipoprotein cholesterol by 73% among people with high-risk hypercholesterolemia, meeting the main goal of a phase 2b study.

The dose-ranging clinical trial, dubbed Etesia, evaluated AZD8233 at 15 mg, 50 mg and 90 mg doses administered monthly via subcutaneous injection within a 12-week period.

Results showed that the drug also cut the PCSK9 enzyme levels by 89%, with sustained reductions observed over the dosing intervals. A decrease in PCSK9 raises LDL receptor levels, which in turn lowers cholesterol levels in the bloodstream, reducing the risk of developing heart disease.

The safety, efficacy and tolerability of AZD8233 in hypercholesterolemia are being examined in the Solano phase 2b trial, with results expected later in the year.

AstraZeneca gained nearly 1% on Monday's close.

Price (GBP): £10142.00, Change: £+66.00, Percent Change: +0.66%

[chc15] 31/3/2022 18:44

Mind u, mkts going down after putins demands, so taking profits not a bad thing.

[chc15] 31/3/2022 18:15

No harm in taking profits, but feel there is good momentum here.

[beckers2008] 31/3/2022 15:48

I'm out at £102. This is above quite a few broker PT's so happy to take profits.
Currently way above 20 mda, too high too quickly, will buy back when it settles.
Good Luck all.

[chc15] 31/3/2022 12:22

We surging here, can only mean there is strong institutional buying at this level, wow.